Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30 expression

Saintes C.; Saint-Jean M.; Renaut J. J.; Dreno B.; Quereux G.

首页> 外文期刊>British Journal of Dermatology >Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30 expression

【24h】

Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30 expression

机译：尽管CD30的表达水平不同，但布仑妥昔单抗维多汀在2例治疗失败后的表皮性皮肤T细胞淋巴瘤患者中具有显着疗效

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《British Journal of Dermatology》 |2015年第3期|共3页
作者
Saintes C.; Saint-Jean M.; Renaut J. J.; Dreno B.; Quereux G.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类皮肤病学与性病学;
关键词

相似文献

外文文献
中文文献
专利

1. Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30 expression [J] . Saintes C., Saint-Jean M., Renaut J. J., British Journal of Dermatology . 2015,第3期

机译：尽管CD30的表达水平不同，但布仑妥昔单抗维多汀在2例治疗失败后的表皮性皮肤T细胞淋巴瘤患者中具有显着疗效
2. Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure [J] . NathwaniN., KrishnanA.Y., HuangQ., Leukemia and lymphoma . 2012,第10期

机译：布伦妥昔单抗维多汀（SGN-35）治疗失败后霍奇金淋巴瘤中CD30表达的持久性
3. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding [J] . Al-Rohil Rami N., Torres-Cabala Carlos A., Patel Anisha, Journal of cutaneous pathology . 2016,第12期

机译：brentuximab vedotin治疗间变性大细胞淋巴瘤患者后CD30表达的丧失：一项新发现
4. New biologic agents for the treatment of cutaneous T-cell lymphoma. [C] . Vittorio CC, Junkins Hopkins JM, McGinnis KS, World Congress on Cancers of the Skin . 2002

机译：用于治疗皮肤T细胞淋巴瘤的新生物剂。
5. Synergy of BCL2 and Histone Deacetylase Inhibition against Leukemic Cells from Cutaneous T-cell Lymphoma Patients [D] . Cyrenne, Benoit M. 2018

机译：BCL2和组蛋白去乙酰化酶抑制作用对皮肤T细胞淋巴瘤患者白血病细胞的协同作用
6. Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin [O] . Mustafa Şahin, Mine Miskioğlu, Işıl Inanır, 2021

机译：皮肤促进大细胞淋巴瘤对Brentuximab Vedotin的戏剧反应
7. PROGNOSTIC FACTORS IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE T-CELL LYMPHOMA (ALCL) RECEIVING BRENTUXIMAB VEDOTIN AND OUTCOME AFTER TREATMENT FAILURE. [O] . Y. Oki, T. Feldman, D. Chihara, 2017

机译：患者预后因素患者复发或难治性全身性大型T细胞淋巴瘤（ALCL）接受Brentuximab vEdotin和治疗后的结果。

Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30 expression

著录项

相似文献

相关主题

期刊订阅